In clinical trials using an ex vivo monocyte-derived DC vaccine to prevent melanoma, GM-CSF and IL-15 treatment preferentially elicited LC-type DC, which are more efficient in priming melanoma-antigen-specific CD8+ T cells in vitro than their monocyte DC counterparts. Here, IL15 is linked to melanoma.